These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34382412)

  • 1. OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
    Gaspar N; Campbell-Hewson Q; Huang J; Okpara CE; Bautista F
    Future Oncol; 2021 Nov; 17(32):4249-4261. PubMed ID: 34382412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
    Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
    Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
    Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
    ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
    Gaspar N; Hung GY; Strauss SJ; Campbell-Hewson Q; Dela Cruz FS; Glade Bender JL; Koh KN; Whittle SB; Chan GC; Gerber NU; Palmu S; Morgenstern DA; Longhi A; Baecklund F; Lee JA; Locatelli F; Márquez Vega C; Janeway KA; McCowage G; McCabe MG; Bidadi B; Huang J; McKenzie J; Okpara CE; Bautista F;
    JAMA Oncol; 2024 Oct; ():. PubMed ID: 39418029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
    Xiao X; Wang W; Wang Z
    Paediatr Drugs; 2014 Dec; 16(6):503-12. PubMed ID: 25392156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.
    Gentet JC; Brunat-Mentigny M; Demaille MC; Pein F; Avet-Loiseau H; Berger C; De Lumley L; Pacquement H; Schmitt C; Sariban E; Pillon P; Bernard JL; Kalifa C
    Eur J Cancer; 1997 Feb; 33(2):232-7. PubMed ID: 9135494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
    Goorin AM; Harris MB; Bernstein M; Ferguson W; Devidas M; Siegal GP; Gebhardt MC; Schwartz CL; Link M; Grier HE
    J Clin Oncol; 2002 Jan; 20(2):426-33. PubMed ID: 11786570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
    Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
    Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
    Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
    Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
    Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
    Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up.
    Aznab M; Hematti M
    J Cancer Res Ther; 2017; 13(2):291-296. PubMed ID: 28643750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
    Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
    J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
    Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F
    Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.